Key Points
- Snehal Patel, CEO of Greenwich LifeSciences, bought 1,800 shares on January 13 at an average price of $29.83 (total $53,694), bringing his holdings to 5,604,102 shares worth roughly $167.17 million (a 0.03% ownership increase).
- Patel has been steadily accumulating stock since October with multiple purchases (e.g., 10,600 shares on Nov 7 at $8.43, 4,300 on Dec 31 at $21.36, and 2,900 on Jan 12 at $27.54), indicating continued insider buying across rising prices.
- GLSI trades around $27.19 with a 1-year range of $7.78–$32.91 and a market cap of about $376.6M; analysts are mixed—HC Wainwright raised its target to $50 (buy), but the consensus rating is a Hold with an average target near $47.50.
Greenwich LifeSciences, Inc. (NASDAQ:GLSI - Get Free Report) CEO Snehal Patel acquired 1,800 shares of the firm's stock in a transaction on Tuesday, January 13th. The shares were bought at an average cost of $29.83 per share, for a total transaction of $53,694.00. Following the completion of the acquisition, the chief executive officer owned 5,604,102 shares of the company's stock, valued at approximately $167,170,362.66. This represents a 0.03% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.
Snehal Patel also recently made the following trade(s):
- On Monday, January 12th, Snehal Patel bought 2,900 shares of Greenwich LifeSciences stock. The shares were bought at an average cost of $27.54 per share, with a total value of $79,866.00.
- On Wednesday, December 31st, Snehal Patel acquired 4,300 shares of Greenwich LifeSciences stock. The shares were purchased at an average price of $21.36 per share, with a total value of $91,848.00.
- On Tuesday, December 30th, Snehal Patel bought 2,900 shares of Greenwich LifeSciences stock. The stock was purchased at an average price of $21.73 per share, for a total transaction of $63,017.00.
- On Thursday, December 18th, Snehal Patel acquired 4,100 shares of Greenwich LifeSciences stock. The stock was acquired at an average price of $12.62 per share, with a total value of $51,742.00.
- On Tuesday, November 25th, Snehal Patel purchased 4,600 shares of Greenwich LifeSciences stock. The stock was bought at an average cost of $8.37 per share, with a total value of $38,502.00.
- On Friday, November 7th, Snehal Patel purchased 10,600 shares of Greenwich LifeSciences stock. The shares were bought at an average price of $8.43 per share, for a total transaction of $89,358.00.
- On Friday, October 31st, Snehal Patel acquired 2,300 shares of Greenwich LifeSciences stock. The shares were purchased at an average price of $9.26 per share, with a total value of $21,298.00.
Greenwich LifeSciences Price Performance
NASDAQ:GLSI opened at $27.19 on Friday. The company's 50-day moving average is $14.04 and its two-hundred day moving average is $11.94. Greenwich LifeSciences, Inc. has a 1-year low of $7.78 and a 1-year high of $32.91. The firm has a market capitalization of $376.58 million, a price-to-earnings ratio of -18.62 and a beta of 1.47.
Greenwich LifeSciences (NASDAQ:GLSI - Get Free Report) last announced its quarterly earnings results on Friday, November 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.30). As a group, equities analysts anticipate that Greenwich LifeSciences, Inc. will post -0.8 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Several equities analysts have recently commented on the company. HC Wainwright upped their price target on Greenwich LifeSciences from $39.00 to $50.00 and gave the company a "buy" rating in a research note on Tuesday, December 30th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Greenwich LifeSciences in a research report on Monday, December 29th. Finally, Wall Street Zen upgraded shares of Greenwich LifeSciences from a "sell" rating to a "hold" rating in a report on Saturday, December 27th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, Greenwich LifeSciences presently has a consensus rating of "Hold" and an average target price of $47.50.
Check Out Our Latest Stock Report on Greenwich LifeSciences
Institutional Trading of Greenwich LifeSciences
Institutional investors and hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. lifted its position in shares of Greenwich LifeSciences by 4.9% during the third quarter. Vanguard Group Inc. now owns 282,181 shares of the company's stock worth $2,808,000 after purchasing an additional 13,179 shares in the last quarter. Geode Capital Management LLC boosted its position in Greenwich LifeSciences by 1.4% in the 2nd quarter. Geode Capital Management LLC now owns 138,982 shares of the company's stock valued at $1,261,000 after buying an additional 1,972 shares during the period. Citadel Advisors LLC grew its stake in shares of Greenwich LifeSciences by 52.1% in the third quarter. Citadel Advisors LLC now owns 20,942 shares of the company's stock worth $208,000 after acquiring an additional 7,174 shares in the last quarter. Marshall Wace LLP purchased a new position in Greenwich LifeSciences in the second quarter valued at $509,000. Finally, Rhumbline Advisers raised its stake in Greenwich LifeSciences by 48.7% in the first quarter. Rhumbline Advisers now owns 9,673 shares of the company's stock valued at $92,000 after buying an additional 3,168 shares in the last quarter. 4.16% of the stock is currently owned by hedge funds and other institutional investors.
About Greenwich LifeSciences
(
Get Free Report)
Greenwich LifeSciences, Inc (NASDAQ: GLSI) is a clinical-stage biotechnology company focused on the development of novel immune modulators for the treatment of cancer and autoimmune diseases. The company's product pipeline includes candidates engineered to activate or regulate key components of the innate and adaptive immune systems, with programs advancing through preclinical and early-stage clinical studies.
Headquartered in Greenwich, Connecticut, Greenwich LifeSciences conducts its research and development activities primarily in the United States.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
